Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kapsula s podaljšanim sproščanjem, trda - tamsulozin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

kapsula s podaljšanim sproščanjem, trda - tamsulozin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

glutaminska kislina; asparaginska kislina; olivno olje, rafinirano; sojino olje, rafinirano; glukoza monohidrat; trigliceridi, srednjeverižni; ribje olje; l-prolin; l-arginin; l-valin; l-levcin; l-histidin; l-triptofan; l-karnitin; l-metionin; l-izolevcin; l-treonin; l-fenilalanin; l-serin; l-alanin; glicil-tirosin dihidrat; glicil-glutamin hidrat; lizinijev acetat - emulzija za infundiranje - glutaminska kislina 2,8 g / 1000 ml  asparaginska kislina1,7 g / 1000 ml  olivno olje, rafinirano12,5 g / 1000 ml  sojino olje, rafinirano15 g / 1000 ml  glukoza monohidrat110 g / 1000 ml  trigliceridi, srednjeverižni15 g / 1000 ml  ribje olje7,5 g / 1000 ml  l-prolin3,4 g / 1000 ml  l-arginin5,65 g / 1000 ml  l-valin3,65 g / 1000 ml  l-levcin3,95 g / 1000 ml  l-histidin3,4 g / 1000 ml  l-triptofan0,95 g / 1000 ml  l-karnitin1 g / 1000 ml  l-metionin2,8 g / 1000 ml  l-izolevcin2,8 g / 1000 ml  l-treonin2,8 g / 1000 ml  l-fenilalanin2,925 g / 1000 ml  l-serin2,25 g / 1000 ml  l-alanin8 g / 1000 ml  glicil-tirosin dihidrat1,725 g / 1000 ml  glicil-glutamin hidrat15,135 g / 1000 ml  lizinijev acetat6,35 g / 1000 ml; asparaginska kislina 1,7 g / 1000 ml  olivno olje, rafinirano12,5 g / 1000 ml  sojino olje, rafinirano15 g / 1000 ml  glukoza monohidrat110 g / 1000 ml  trigliceridi, srednjeverižni15 g / 1000 ml  ribje olje7,5 g / 1000 ml  l-prolin3,4 g / 1000 ml  l-arginin5,65 g / 1000 ml  l-valin3,65 g / 1000 ml  l-levcin3,95 g / 1000 ml  l-histidin3,4 g / 1000 ml  l-triptofan0,95 g / 1000 ml  l-karnitin1 g / 1000 ml  l-metionin2,8 g / 1000 ml  l-izolevcin2,8 g / 1000 ml  l-treonin2,8 g / 1000 ml  l-fenilalanin2,925 g / 1000 ml  l-serin2,25 g / 1000 ml  l-alanin8 g / 1000 ml  glicil-tirosin dihidrat1,725 g / 1000 ml  glicil-glutamin hidrat15,135 g / 1000 ml  lizinijev acetat6,35 g / 1000 ml; olivno olje, rafinirano 12,5 g / 1000 ml  sojino olje, rafinirano15 g / 1000 ml  glukoza monohidrat110 g / 1000 ml  trigliceridi, srednjeverižni15 g / 1000 ml  ribje olje7,5 g / 1000 ml  l-prolin3,4 g / 1000 ml  l-arginin5,65 g / 1000 ml  l-valin3,65 g / 1000 ml  l-levcin3,95 g / 1000 ml  l-histidin3,4 g / 1000 ml  l - kombinacije

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

medis, d.o.o. - glicin; glutaminska kislina; histidin; alanin; arginin; asparaginska kislina; cistein; fenilalanin; izolevcin; levcin; lizin; metionin; prolin; serin; treonin; triptofan; valin; tirosin - raztopina za infundiranje - glicin 19,2 mg / 1 ml  glutaminska kislina16,2 mg / 1 ml  histidin5,25 mg / 1 ml  alanin22,35 mg / 1 ml  arginin16,05 mg / 1 ml  asparaginska kislina7,95 mg / 1 ml  cistein0,37 mg / 1 ml  fenilalanin5,7 mg / 1 ml  izolevcin5,85 mg / 1 ml  levcin11,4 mg / 1 ml  lizin7,95 mg / 1 ml  metionin5,7 mg / 1 ml  prolin7,35 mg / 1 ml  serin3 mg / 1 ml  treonin5,4 mg / 1 ml  triptofan2,1 mg / 1 ml  valin7,2 mg / 1 ml  tirosin0,5 mg / 1 ml; glutaminska kislina 16,2 mg / 1 ml  histidin5,25 mg / 1 ml  alanin22,35 mg / 1 ml  arginin16,05 mg / 1 ml  asparaginska kislina7,95 mg / 1 ml  cistein0,37 mg / 1 ml  fenilalanin5,7 mg / 1 ml  izolevcin5,85 mg / 1 ml  levcin11,4 mg / 1 ml  lizin7,95 mg / 1 ml  metionin5,7 mg / 1 ml  prolin7,35 mg / 1 ml  serin3 mg / 1 ml  treonin5,4 mg / 1 ml  triptofan2,1 mg / 1 ml  valin7,2 mg / 1 ml  tirosin0,5 mg / 1 ml; histidin 5,25 mg / 1 ml  alanin22,35 mg / 1 ml  arginin16,05 mg / 1 ml  asparaginska kislina7,95 mg / 1 ml  cistein0,37 mg / 1 ml  fenilalanin5,7 mg / 1 ml  izolevcin5,85 mg / 1 ml  levcin11,4 mg / 1 ml  lizin7,95 mg / 1 ml  metionin5,7 mg / 1 ml  prolin7,35 mg / 1 ml  serin3 mg / 1 ml  treonin5,4 mg / 1 ml  triptofan2,1 mg / 1 ml  valin7,2 mg / 1 ml  tirosin0,5 mg / 1 ml; alanin 22,35 mg / 1 ml  arginin16,05 mg / 1 ml  asparaginska kislina7,95 mg / 1 ml  cistein0,37 mg / 1 ml  fenilalanin5,7 mg / 1 ml  izolevcin5,85 mg / 1 ml  levcin11,4 mg / 1 ml  lizin7,95 mg / 1 ml  metionin5,7 mg / 1 ml  prolin7,35 mg / 1 ml  serin3 mg / 1 ml  treonin5,4 mg / 1 ml  triptofan2,1 mg / 1 ml  valin7,2 mg / 1 ml  tirosin0,5 mg / 1 ml; arginin 16,05 mg / 1 ml  asparaginska kislina7,95 mg / 1 ml  cistein0,37 mg / 1 ml &nbs - aminokisline

Evropska unija - slovenščina - EMA (European Medicines Agency)

swedish orphan biovitrum international ab - nitizinon - tyrosinemias - drugi zdravljene bolezni prebavil in presnove izdelki, - hereditary tyrosinemia type 1 (ht 1)orfadin is indicated for the treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht 1) in combination with dietary restriction of tyrosine and phenylalanine. alkaptonuria (aku)orfadin is indicated for the treatment of adult patients with alkaptonuria (aku).

Evropska unija - slovenščina - EMA (European Medicines Agency)

cycle pharmaceuticals (europe) ltd - nitizinon - tyrosinemias - drugi zdravljene bolezni prebavil in presnove izdelki, - za zdravljenje odraslih in pediatričnih bolnikih s potrjeno diagnozo dedno tyrosinemia tip 1 (ht-1) v kombinaciji z prehranskih omejitev tirozin in fenilalanin.

Evropska unija - slovenščina - EMA (European Medicines Agency)

mendelikabs europe ltd - nitizinon - tyrosinemias - drugi zdravljene bolezni prebavil in presnove izdelki, - zdravljenje odraslih in pediatričnih bolnikov s katero je bila potrjena diagnoza dedne tipografije tipa 1 (ht 1) v kombinaciji s prehransko omejitvijo tirozina in fenilalanina.

Evropska unija - slovenščina - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - predkroglomerna limfoblastna levkemija limfoma - antineoplastična sredstva - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Evropska unija - slovenščina - EMA (European Medicines Agency)

novartis europharm ltd - midostaurin - leukemia, myeloid, acute; mastocytosis - antineoplastična sredstva - rydapt je navedeno:v kombinaciji s standardno daunorubicin in cytarabine indukcije in visok odmerek cytarabine konsolidacije kemoterapijo, in za bolnike v popolni odgovor sledi rydapt en agent za vzdrževanje terapija, pri odraslih bolnikih, ki so na novo zboleli za akutno mieloično levkemijo (aml), ki so flt3 mutacije pozitivna (glej poglavje 4. 2);kot monotherapy za zdravljenje odraslih bolnikov z agresivno sistemske mastocytosis (asm), sistemsko mastocytosis s povezanimi hematoloških neoplasm (sm ahn), ali jambor celice levkemijo (mcl).

Evropska unija - slovenščina - EMA (European Medicines Agency)

pfizer europe ma eeig - lorlatinib - karcinom, pljučni pljuč - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.